Establishment of Biomarker Panel May Lead to Rapid Tests for Early Diagnosis of Pancreatic Cancer
|
By LabMedica International staff writers Posted on 10 Apr 2016 |
|
Image: Micrograph of pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) (Photo courtesy of Wikimedia Commons).
A panel comprising five genetic biomarkers was shown to accurately differentiate among tissues from pancreatic tumors and those taken from various non-malignant sources.
Investigators at Beth Israel Deaconess Medical Center (Boston, MA, USA) applied innovative data normalization and gene selection approaches to analyze a number of publicly available pancreatic cancer gene expression datasets. They combined the statistical power of multiple genomic studies while masking their variability and batch effects to identify robust early diagnostic biomarkers of pancreatic cancer.
The investigators established a panel comprising the genes TMPRSS4 (Transmembrane protease, serine 4), AHNAK2 (AHNAK nucleoprotein 2), POSTN (Periostin), ECT2 (Epithelial cell transforming 2), and SERPINB5 (Serpin peptidase inhibitor, clade B (ovalbumin), member 5) that achieved on average 95% sensitivity and 89% specificity in discriminating pancreatic ductal adenocarcinoma (PDAC) from non-tumor samples in four training sets and similar performance in five independent validation datasets. The five-gene classifier accurately discriminated PDAC from chronic pancreatitis, other cancers, and non-tumor samples from PDAC precursors in three independent datasets.
PDAC-specific expression of the biomarker panel was measured by qRT-PCR (qualitative real-time PCR) in microdissected patient-derived FFPE (formalin-fixed, paraffin-embedded) tissues. Cell-based assays were then used to assess the impact of two of the biomarkers, TMPRSS4 and ECT2, on PDAC cells.
Results revealed that knock-down of TMPRSS4 and ECT2 reduced PDAC soft agar growth and cell viability, and TMPRSS4 knockdown also blocked PDAC migration and invasion.
“Pancreatic cancer is a devastating disease with a death rate close to the incidence rate,” said senior author Dr. Towia Libermann, professor of medicine at Beth Israel Deaconess Medical Center. “Because more than 90% of pancreatic cancer cases are diagnosed at the metastatic stage, when there are only limited therapeutic options, earlier diagnosis is anticipated to have a major impact on extending life expectancy for patients. There has been a lack of reliable markers, early indicators, and risk factors associated with pancreatic cancer, but this new way of differentiating between healthy and malignant tissue offers hope for earlier diagnosis and treatment.”
“Because these five genes are turned on so early in the development of pancreatic cancer, they may play roles as drivers of this disease and may be exciting targets for therapies,” said Dr. Libermann. “Moving forward, we will explore the potential to convert this tissue-based diagnostic into a noninvasive blood or urine test.”
The study was published in the March 16, 2016, online edition of the journal Oncotarget.
Related Links:
Beth Israel Deaconess Medical Center
 Assay.jpg)
Investigators at Beth Israel Deaconess Medical Center (Boston, MA, USA) applied innovative data normalization and gene selection approaches to analyze a number of publicly available pancreatic cancer gene expression datasets. They combined the statistical power of multiple genomic studies while masking their variability and batch effects to identify robust early diagnostic biomarkers of pancreatic cancer.
The investigators established a panel comprising the genes TMPRSS4 (Transmembrane protease, serine 4), AHNAK2 (AHNAK nucleoprotein 2), POSTN (Periostin), ECT2 (Epithelial cell transforming 2), and SERPINB5 (Serpin peptidase inhibitor, clade B (ovalbumin), member 5) that achieved on average 95% sensitivity and 89% specificity in discriminating pancreatic ductal adenocarcinoma (PDAC) from non-tumor samples in four training sets and similar performance in five independent validation datasets. The five-gene classifier accurately discriminated PDAC from chronic pancreatitis, other cancers, and non-tumor samples from PDAC precursors in three independent datasets.
PDAC-specific expression of the biomarker panel was measured by qRT-PCR (qualitative real-time PCR) in microdissected patient-derived FFPE (formalin-fixed, paraffin-embedded) tissues. Cell-based assays were then used to assess the impact of two of the biomarkers, TMPRSS4 and ECT2, on PDAC cells.
Results revealed that knock-down of TMPRSS4 and ECT2 reduced PDAC soft agar growth and cell viability, and TMPRSS4 knockdown also blocked PDAC migration and invasion.
“Pancreatic cancer is a devastating disease with a death rate close to the incidence rate,” said senior author Dr. Towia Libermann, professor of medicine at Beth Israel Deaconess Medical Center. “Because more than 90% of pancreatic cancer cases are diagnosed at the metastatic stage, when there are only limited therapeutic options, earlier diagnosis is anticipated to have a major impact on extending life expectancy for patients. There has been a lack of reliable markers, early indicators, and risk factors associated with pancreatic cancer, but this new way of differentiating between healthy and malignant tissue offers hope for earlier diagnosis and treatment.”
“Because these five genes are turned on so early in the development of pancreatic cancer, they may play roles as drivers of this disease and may be exciting targets for therapies,” said Dr. Libermann. “Moving forward, we will explore the potential to convert this tissue-based diagnostic into a noninvasive blood or urine test.”
The study was published in the March 16, 2016, online edition of the journal Oncotarget.
Related Links:
Beth Israel Deaconess Medical Center
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Gold Member
Platelet Function Analyzer
PL-12
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Latest Pathology News
- AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
- FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
- Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
- Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
- New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
- EBV Status Helps Predict Survival in Primary CNS Lymphoma
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Channels
Clinical Chemistry
view channel
AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer
Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more
Compact Prenatal Screening System Expands Access to Preeclampsia Testing
Preeclampsia affects an estimated 2%–8% of pregnancies and is rising globally with increasing maternal age, diabetes, and hypertension. While international guidelines recommend screening, access often... Read more
Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more
Molecular Diagnostics
view channel
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more
Liquid Biopsy Combines Multiple Signals for Cancer Detection in a Single Analysis
Detecting and monitoring cancer often requires repeated tissue biopsies, which are invasive and not always feasible. Liquid biopsy offers a less invasive way to track disease over time, but many assays... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read more
Microbiology
view channel
FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more